Mucopolysaccharidosis I (MPS I) Registry
2 other identifiers
observational
1,406
37 countries
141
Brief Summary
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are:
- To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)
- To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
- To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2003
Longer than P75 for all trials
141 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 20, 2003
CompletedFirst Submitted
Initial submission to the registry
September 2, 2005
CompletedFirst Posted
Study publicly available on registry
September 5, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedFebruary 27, 2026
February 1, 2026
21.1 years
September 2, 2005
February 24, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the long-term effectiveness of Aldurazyme
Approximately 17 Years
Eligibility Criteria
All Patients with MPS I
You may qualify if:
- For all patients there should be a completed patient authorization form
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (141)
Phoenix Children's Hospital- Site Number : 840003
Phoenix, Arizona, 85016, United States
Arkansas Children's Hospital- Site Number : 840109
Little Rock, Arkansas, 72202, United States
Southern California Permanente Medical Group- Site Number : 840108
Los Angeles, California, 90027, United States
USC Health Sciences Center Dept of Genetics- Site Number : 840082
Los Angeles, California, 90033, United States
UCSF Benioff Children's Hospital - Oakland- Site Number : 840029
Oakland, California, 94609, United States
Children's Hospital of Orange County- Site Number : 840074
Orange, California, 92868, United States
Stanford Unviersity MC Dept of Genetics- Site Number : 840022
Palo Alto, California, 94305, United States
UC Davis MIND Institute- Site Number : 840010
Sacramento, California, 95817, United States
University of California at San Diego- Site Number : 840007
San Diego, California, 92093, United States
University of California at San Francisco- Site Number : 840051
San Francisco, California, United States
Children's Hospital Colorado - Aurora- Site Number : 840069
Aurora, Colorado, 80045, United States
University of Colorado at Denver Genetics Site Number : 840068
Aurora, Colorado, 80045, United States
Yale University School of Medicine- Site Number : 840047
New Haven, Connecticut, 06510, United States
Children's National Medical Center - Washington- Site Number : 840067
Washington D.C., District of Columbia, 20010, United States
University of Florida Dept of Genetics- Site Number : 840083
Gainesville, Florida, 32610, United States
University Of Miami SOM- Site Number : 840006
Miami, Florida, 33136, United States
Pediatric Endocrine Associates- Site Number : 840017
Tampa, Florida, 33612, United States
Emory University School of Medicine- Human Genetics- Site Number : 840060
Decatur, Georgia, 30033, United States
Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 840011
Chicago, Illinois, 60611, United States
Rush University Medical Center Genetics- Site Number : 840079
Chicago, Illinois, 60612, United States
Indianapolis University School of Medicine- Site Number : 840027
Indianapolis, Indiana, 46202, United States
University of Iowa- Site Number : 840032
Iowa City, Iowa, 52242, United States
University of Louisville- Genetics- Site Number : 840030
Louisville, Kentucky, 40202, United States
John Hopkins- Site Number : 840044
Baltimore, Maryland, United States
Massachusetts General Hospital-Genetics- Site Number : 840062
Boston, Massachusetts, 02114, United States
Boston Children's Hospital - PIN- Site Number : 840093
Boston, Massachusetts, 2115, United States
Baystate Medical Center- Site Number : 840002
Springfield, Massachusetts, 01199, United States
University of Michigan Pediatrics- Site Number : 840107
Ann Arbor, Michigan, 48109, United States
University of Minnesota Medical Center Pediatrics- Site Number : 840076
Minneapolis, Minnesota, 55455, United States
Washington University- Site Number : 840100
St Louis, Missouri, 63110, United States
University of Nebraska Medical Center- Site Number : 840084
Omaha, Nebraska, 68198, United States
Children's Specialty Center - Las Vegas- Site Number : 840008
Las Vegas, Nevada, 89109, United States
Joseph M. Sanzari Children's Hospital- Site Number : 840101
Hackensack, New Jersey, 07601, United States
Saint Peter's University Hospital - New Brunswick- Site Number : 840016
New Brunswick, New Jersey, 08901, United States
Northwell Health - Site Number : 840102
Manhasset, New York, 11030, United States
New York University School Of Medicine- Site Number : 840040
New York, New York, 10016, United States
State University of New York- Site Number : 840052
Syracuse, New York, 13210, United States
Duke University Medical Center Genetics Dept- Site Number : 840037
Durham, North Carolina, 27710, United States
Cincinnati Children's Hospital-Genetics- Site Number : 840041
Cincinnati, Ohio, United States
Nationwide Children's Hospital- Site Number : 840091
Columbus, Ohio, 43205, United States
Oregon Health & Science University (OHSU)- Site Number : 840080
Portland, Oregon, 97239, United States
Children's Hospital of Philadelphia HUP Medical Genetics- Site Number : 840089
Philadelphia, Pennsylvania, 19104, United States
Children's Hospital of Philadelphia- Site Number : 840034
Philadelphia, Pennsylvania, United States
University of Pittsburgh- Site Number : 840023
Pittsburgh, Pennsylvania, 15224, United States
Rhode Island Hospital Genetics- Site Number : 840053
Providence, Rhode Island, 02903, United States
Greenwood Genetic Center - Greenville- Site Number : 840055
Greenville, South Carolina, 29605, United States
Baylor Institute of Metabolic Disease- Site Number : 840058
Dallas, Texas, 75226, United States
University of Utah Health Hospital- Site Number : 840092
Salt Lake City, Utah, 84132, United States
University of Virginia School of Medicine-Pediatrics- Site Number : 840078
Charlottesville, Virginia, 22908, United States
Children's Hospital of The King's Daughters- Site Number : 840072
Norfolk, Virginia, 23507, United States
Seattle Children's Hospital- Site Number : 840028
Seattle, Washington, 98105, United States
University Of Washington Medical Center- Site Number : 840059
Seattle, Washington, 98195, United States
Children's Hospital of Wisconsin-Pediatrics- Site Number : 840054
Milwaukee, Wisconsin, 53226, United States
Investigational Site Number : 153032
Buenos Aires, 1192, Argentina
Investigational Site Number : 153130
San Luis, 5700, Argentina
Investigational Site Number : 151069
Westmead, New South Wales, 2145, Australia
Investigational Site Number : 150944
Brussels, 1090, Belgium
Investigational Site Number : 151668
Leuven, 3000, Belgium
Investigational Site Number : 154008
Roeselare, 8800, Belgium
Private Practice - Dr. Fabiano Klaus- Site Number : 076001
Porto Alegre, Rio Grande do Sul, 90035-002, Brazil
Hospital e Maternidade Celso Pierro - PUC-Campinas- Site Number : 076007
Campinas, São Paulo, 13034-685, Brazil
Instituto Fernandes Figueira - FIOCRUZ- Site Number : 076004
Rio de Janeiro, 22250-020, Brazil
Instituto de Genética e Erros Inatos do Metabolismo- Site Number : 076002
São Paulo, 04020-041, Brazil
Investigational Site Number : 124014
Calgary, Alberta, T2E 7Z4, Canada
Investigational Site Number : 124002
Edmonton, Alberta, T6G 2B7, Canada
Investigational Site Number : 124011
Vancouver, British Columbia, V6H 3N1, Canada
Investigational Site Number : 124019
Winnipeg, Manitoba, R3A 1R9, Canada
Investigational Site Number : 124021
London, Ontario, N6A 5A5, Canada
Investigational Site Number : 124018
Ottawa, Ontario, K1K 4L2, Canada
Investigational Site Number : 124006
Toronto, Ontario, M5G 1X8, Canada
Investigational Site Number : 124001
Sherbrooke, Quebec, J1K 2R1, Canada
Investigational Site Number : 152001
Talcahuano, Región del Biobío, 2687000, Chile
Investigational Site Number : 152003
Los Ángeles, Chile
Investigational Site Number : 170001
Bogotá, Colombia
Investigational Site Number : 150659
Prague, 12808, Czechia
Investigational Site Number : 151229
Copenhagen, 2100, Denmark
Investigational Site Number : 818002
Cairo, 11231, Egypt
Investigational Site Number : 818001
Cairo, Egypt
Investigational Site Number : 250004
Bordeaux, 33076, France
Investigational Site Number : 250001
Bron, 69677, France
Investigational Site Number : 250002
Marseille, 13885, France
Investigational Site Number : 250003
Paris, 75015, France
Investigational Site Number : 250006
Vandœuvre-lès-Nancy, 54511, France
Investigational Site Number : 151368
Hamburg, 20246, Germany
Investigational Site Number : 150031
Mainz, 55131, Germany
Investigational Site Number : 344001
Kowloon, Hong Kong
Investigational Site Number : 356003
Ahmedabad, 380015, India
Investigational Site Number : 356001
Kolkata, 700017, India
Investigational Site Number : 356002
Vellore, 632004, India
Investigational Site Number : 360001
Jakarta, Indonesia
Investigational Site Number : 154161
Dublin, D01 F772, Ireland
Investigational Site Number : 380004
Cusano Milanino, Milano, 20095, Italy
Investigational Site Number : 380007
Milan, Milano, 20142, Italy
Investigational Site Number : 380006
Rome, Roma, 00165, Italy
Investigational Site Number : 380002
Ancona, 60126, Italy
Investigational Site Number : 380003
Genova, 16147, Italy
Investigational Site Number : 380005
Naples, Italy
Investigational Site Number : 380008
Padua, 35128, Italy
Investigational Site Number : 392102
Nankoku, Kochi, 783-8505, Japan
Investigational Site Number : 392101
Tokyo, 157-8535, Japan
Investigational Site Number : 154225
Kuwait City, Kuwait
Investigational Site Number : 4220004
Beirut, 11072210, Lebanon
Investigational Site Number : 458001
Kuala Lumpur, 50586, Malaysia
Investigational Site Number : 458002
Kuala Lumpur, 59100, Malaysia
Investigational Site Number : 151171
Amsterdam, Netherlands
Investigational Site Number : 152029
Rotterdam, 3015 CE, Netherlands
Investigational Site Number : 154264
Lahore, Pakistan
Investigational Site Number : 154266
Lahore, Pakistan
Investigational Site Number : 608001
Manila, 1000, Philippines
Investigational Site Number : 150575
Warsaw, 04-730, Poland
Investigational Site Number : 6200002
Coimbra, 3000-075, Portugal
Investigational Site Number : 154177
Cluj-Napoca, 400006, Romania
Investigational Site Number : 643001
Moscow, 119571, Russia
Investigational Site Number : 643002
Moscow, 125412, Russia
Investigational Site Number : 682001
Al Qaţīf, Saudi Arabia
Investigational Site Number : 682004
Mecca, 24246, Saudi Arabia
Investigational Site Number : 703001
Bratislava, 833 40, Slovakia
Investigational Site Number : 153191
Daejeon, South Korea
Investigational Site Number : 153225
Jeonnam, South Korea
Investigational Site Number : 153212
Seoul, South Korea
Investigational Site Number : 153222
Seoul, South Korea
Investigational Site Number : 7520001
Stockholm, 171 76, Sweden
Investigational Site Number : 154093
Chiayi City, Taiwan
Investigational Site Number : 152246
Kaohsiung City, 833, Taiwan
Investigational Site Number : 151500
Putz City, Chia-yi, Taiwan
Investigational Site Number : 151179
Taichung, 404, Taiwan
Investigational Site Number : 152153
Tainan, 710, Taiwan
Investigational Site Number : 151182
Taipei, 100, Taiwan
Investigational Site Number : 152321
Taipei, 104, Taiwan
Investigational Site Number : 764002
Bangkok, 10400, Thailand
Investigational Site Number : 764003
Bangkok, 10400, Thailand
Investigational Site Number : 764004
Bangkok, 10700, Thailand
Investigational Site Number : 764001
Bangkok, Thailand
Investigational Site Number : 154240
Birmingham, England, B4 6NH, United Kingdom
Investigational Site Number : 151123
London, England, NW3 2QG, United Kingdom
Investigational Site Number : 152156
Glasgow, Glasgow City, G51 4TF, United Kingdom
Investigational Site Number : 151646
London, London, City of, WC1N 3BG, United Kingdom
Investigational Site Number : 150303
London, London, City of, WC1N 3JH, United Kingdom
Investigational Site Number : 152361
Salford, Manchester, M6 8HD, United Kingdom
Investigational Site Number : 150455
Manchester, Missouri, M13 9WL, United Kingdom
Investigational Site Number : 154212
Hanoi, Vietnam
Related Publications (3)
Viskochil D, Muenzer J, Guffon N, Garin C, Munoz-Rojas MV, Moy KA, Hutchinson DT. Carpal tunnel syndrome in mucopolysaccharidosis I: a registry-based cohort study. Dev Med Child Neurol. 2017 Dec;59(12):1269-1275. doi: 10.1111/dmcn.13545. Epub 2017 Sep 11.
PMID: 28892147BACKGROUNDArn P, Bruce IA, Wraith JE, Travers H, Fallet S. Airway-related symptoms and surgeries in patients with mucopolysaccharidosis I. Ann Otol Rhinol Laryngol. 2015 Mar;124(3):198-205. doi: 10.1177/0003489414550154. Epub 2014 Sep 11.
PMID: 25214650BACKGROUNDBeck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, Fallet S. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014 Oct;16(10):759-65. doi: 10.1038/gim.2014.25. Epub 2014 Mar 27.
PMID: 24675674BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Genzyme, a Sanofi Company
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 2, 2005
First Posted
September 5, 2005
Study Start
November 20, 2003
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
February 27, 2026
Record last verified: 2026-02